Markets Cantor starts Mainz Biomed at OW; PT $15 Cantor Fitzgerald launched coverage of Mainz Biomed B.V. (NASDAQ:MYNZ) with an “overweight” rating and 12-month price target of $15. The stock closed at $6.63 on Oct. 24. MYNZ develops market-ready molecular genetic... October 25, 2022